Acadia Pharmaceuticals price target raised to $20 from $19 at Mizuho

Mizuho analyst Uy Ear raised the firm’s price target on Acadia Pharmaceuticals to $20 from $19 and keeps a Neutral rating on the shares after the company hosed a call to discuss Friday’s FDA approval of Daybue in Rett syndrome. Profit taking and investors looking for a more catalyst-rich stock might have led to yesterday’s selloff, the analyst tells investors in a research note. The firm says the label was largely as expected while pricing came in better than expected.